FibroBiologics (NASDAQ:FBLG) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a report published on Friday,Benzinga reports. They currently have a $16.00 price target on the stock.

A number of other research analysts have also issued reports on FBLG. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of FibroBiologics in a report on Wednesday, November 13th. EF Hutton Acquisition Co. I raised FibroBiologics to a “strong-buy” rating in a report on Wednesday, September 4th. Maxim Group initiated coverage on FibroBiologics in a research report on Tuesday, September 24th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Rodman & Renshaw started coverage on shares of FibroBiologics in a research note on Thursday, December 12th. They set a “buy” rating and a $12.00 target price for the company. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, FibroBiologics presently has an average rating of “Buy” and an average price target of $13.00.

FibroBiologics Stock Up 2.2 %

Shares of FBLG stock opened at $2.36 on Friday. The business’s fifty day moving average price is $2.66 and its 200 day moving average price is $3.23. FibroBiologics has a 1-year low of $1.08 and a 1-year high of $55.00.

Institutional Trading of FibroBiologics

Several large investors have recently added to or reduced their stakes in FBLG. Charles Schwab Investment Management Inc. raised its stake in shares of FibroBiologics by 5.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 69,732 shares of the company’s stock valued at $215,000 after purchasing an additional 3,451 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of FibroBiologics during the third quarter valued at approximately $32,000. Mercer Global Advisors Inc. ADV bought a new stake in FibroBiologics during the second quarter worth approximately $51,000. Jane Street Group LLC acquired a new stake in FibroBiologics in the third quarter worth approximately $37,000. Finally, Cahaba Wealth Management Inc. acquired a new position in shares of FibroBiologics during the 2nd quarter valued at $73,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.